Lilly to sell hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals
Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 billion. BAQSIMI is indicated for the treatment of severe hypoglycemia, which is very low blood sugar, in people with diabetes aged four years and over. It is the first as […]